Antibodies binding to HLA-A2/MAGE-A4

An antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising

• (i) a heavy chain variable region (VH) comprising a heavy chain complementary determining region (HCDR) 1 of SEQ ID NO:
• 25, a HCDR 2 of SEQ ID NO:
• 26, and a HCDR 3 of SEQ ID NO:
• 27, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:
• 28, a LCDR 2 of SEQ ID NO:
• 29 and a LCDR 3 of SEQ ID NO:
• 30;
• (ii) a VH comprising a HCDR 1 of SEQ ID NO:
• 1, a HCDR 2 of SEQ ID NO:
• 2, and a HCDR 3 of SEQ ID NO:
• 3, and a VL comprising a LCDR 1 of SEQ ID NO:
• 4, a LCDR 2 of SEQ ID NO:
• 5 and a LCDR 3 of SEQ ID NO:
• 6;
• (iii) a VH comprising a HCDR 1 of SEQ ID NO:
• 41, a HCDR 2 of SEQ ID NO:
• 42, and a HCDR 3 of SEQ ID NO:
• 43, and a VL comprising a LCDR 1 of SEQ ID NO:
• 44, a LCDR 2 of SEQ ID NO:
• 45 and a LCDR 3 of SEQ ID NO:
• 46;
• (iv) a VH comprising a HCDR 1 of SEQ ID NO:
• 9, a HCDR 2 of SEQ ID NO:
• 10, and a HCDR 3 of SEQ ID NO:
• 11, and a VL comprising a LCDR 1 of SEQ ID NO:
• 12, a LCDR 2 of SEQ ID NO:
• 13 and a LCDR 3 of SEQ ID NO:
• 14;
• (v) a VH comprising a HCDR 1 of SEQ ID NO:
• 17, a HCDR 2 of SEQ ID NO:
• 18, and a HCDR 3 of SEQ ID NO:
• 19, and a VL comprising a LCDR 1 of SEQ ID NO:
• 20, a LCDR 2 of SEQ ID NO:
• 21 and a LCDR 3 of SEQ ID NO:
• 22;
• or
• (vi) a VH comprising a HCDR 1 of SEQ ID NO:
• 33, a HCDR 2 of SEQ ID NO:
• 34, and a HCDR 3 of SEQ ID NO:
• 35, and a VL comprising a LCDR 1 of SEQ ID NO:
• 36, a LCDR 2 of SEQ ID NO:
• 37 and a LCDR 3 of SEQ ID NO:
• 38.